SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (Belite Bio or the Company), a clinical-stage biopharmaceutical drug development company focused on advancing novel...
Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results
Belite Bio Announces Availability of Annual Report on Form 20-F
Belite Bio to Discuss Fourth Quarter and Full Year 2024 Financial Results
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Completed enrollment in pivotal Phase 3 œDRAGON trial for Tinlarebant in adolescent Stargardt disease (œSTGD1) with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with...